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Abstract
Myeloproliferative neoplasms (MPNs) are developing resistance to therapy by JAK1/2 inhibitor 
ruxolitinib. To explore the mechanism of ruxolitinib’s limited effect, we examined the JAK1/2 
mediated induction of proliferation related ERK1/2 and AKT signaling by proinflammatory 
interleukin-6 (IL-6) in MPN granulocytes and JAK2V617F mutated human erythroleukemia 
(HEL) cells. We found that JAK1/2 or JAK2 inhibition prevented the IL-6 activation of STAT3 and 
AKT pathways in polycythemia vera and HEL cells. Further, we showed that these inhibitors also 
blocked the IL-6 activation of the AKT pathway in primary myelofibrosis (PMF). Only JAK1/2 
inhibitor ruxolitinib largely activated ERK1/2 signaling in essential thrombocythemia and PMF 
(up to 4.6 fold), with a more prominent activation in JAK2V617F positive granulocytes. Regarding 
a cell cycle, we found that IL-6 reduction of HEL cells percentage in G2M phase was reversed by 
ruxolitinib (2.6 fold). Moreover, ruxolitinib potentiated apoptosis of PMF granulocytes (1.6 fold). 
Regarding DNA replication, we found that ruxolitinib prevented the IL-6 augmentation of MPN 
granulocytes frequency in the S phase of the cell cycle (up to 2.9 fold). The inflammatory 
stimulation induces a cross-talk between the proliferation linked pathways, where JAK1/2 
inhibition is compensated by the activation of the ERK1/2 pathway during IL-6 stimulation of 
DNA replication.
Corresponding author: Vladan P. Čokić, Department of Molecular Oncology, Institute for Medical Research, University of Belgrade, 
Dr. Subotica 4, 11129 Belgrade, Serbia, Phone: +381112684484, Fax: +381112643691, vl@imi.bg.ac.rs. 
Conflict of interest
The authors have declared that no competing interests exist.
HHS Public Access
Author manuscript
Cell Biol Int. Author manuscript; available in PMC 2020 February 01.
Published in final edited form as:














cell cycle; ERK1/2 signaling; inflammation; JAK1/2 inhibition; myeloproliferative neoplasm
1. Introduction
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders 
associated with genomic instability, dysregulated signaling pathways and chronic 
inflammation (Hasselbalch 2012). The most common feature of MPN is acquired somatic 
JAK2V617F mutation that induces constitutive activation of signal transducer and activator 
of transcription 3 (STAT3) and downstream mitogen-activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3K)/AKT signaling (Oku et al 2010; Mendoza et al. 2011). 
We already reported that STAT3 has been significantly increased in JAK2V617F 
homozygous polycythemia vera (PV), besides increased levels of proinflammatory mediator 
interleukin-6 (IL-6) in plasma and the bone marrow stroma of MPN (Čokić et al. 2015) The 
constitutive STAT3 activation increases myeloproliferation and inflammation by promoting 
pro-oncogenic inflammatory pathways, including IL-6 - Janus kinase (JAK) pathway (Oku 
et al 2010; Reynaud et al. 2011). The JAK2V617F presence correlates with increased levels 
of IL-6 in the plasma of patients with primary myelofibrosis (PMF), associated with 
shortened survival (Tefferi et al. 2011). Therefore, the inflammatory stimulation of JAK-
STAT3 signaling is potentiated by constitutive JAK2 activation that supports excessive 
proliferation in MPN.
MPN derived granulocytes, regardless the JAK2 mutational status, are characterized by the 
upregulation of JAK-STAT target genes, demonstrating the central role of the JAK-STAT 
pathway in the pathogenesis of MPN (Rampal et al. 2014). A significantly higher 
phosphorylation of STAT3 in JAK2V617F positive MPN patients, which are not dependent 
on the mutation allele burden, has been demonstrated (Risum et al. 2011). Moreover, JAK2 
inhibition reduces STAT3 phosphorylation in PMF granulocytes, and it is also not affected 
by JAK2V617F allele burden (Kalota et al. 2013). In contrast, the gene expression profile is 
different between JAK2V617F-negative and JAK2V617F-positive essential 
thrombocythemia (ET) patients in circulating granulocytes (Schwemmers et al. 2007; 
Puigdecanet et al. 2008). Furthermore, the constitutive phosphorylation of STAT3 is 
observed in the neutrophils of MPN patients with high and intermediate JAK2V617F mutant 
allele burden, while the phosphorylation of AKT and MAPK signaling failed to correlate 
with the JAK2 mutation status (Mesa et al. 2006). The inhibition of PI3K-AKT signaling 
prevented the colony formation of JAK2V617F-expressing CD34+ cells and hematopoietic 
progenitors in patients with PMF (Khan et al. 2013). The combination of JAK1/2 and PI3K 
inhibitors reduced the spleen weight and erythropoietin-independent erythroid colony 
growth of MPN patients and JAK2V617F knock-in mice (Choong et al. 2013). Thus, the 
constitutive activation of JAK2-STAT3 signaling is supported by the PI3K-AKT pathway.
IL-6 dictates the transition from acute to chronic inflammation by transforming granulocytes 
to monocytes/macrophages, with a proinflammatory role in the chronic inflammation (Rose-
John et al. 2006). We hypothesized that the IL-6 interaction with MAPK and PI3K-AKT 
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pathways is a potential subsidiary mechanism of the proliferation control in cross-talk with 
the constitutively activated JAK-STAT signaling in MPN. In accordance with our earlier 
report, we subsequently analyzed how JAK1/2 mediated the IL-6 regulation of cell 
proliferation and the activation of STAT3, AKT, and MAPK pathways in the human 
erythroleukemia (HEL) cellular model and MPN granulocytes.
2. Material and methods
2.1 HEL 92.1.7 and chronic myelogenous leukemia K562 cell lines
HEL 92.1.7 cells with a homozygous expression of JAK2V617F, and K562 cells, were 
cultivated in an RPMI-1640 medium (Biowest, Nuaillé, France) containing 10% fetal bovine 
serum (FBS, Biowest) and 1% penicillin-streptomycin (Biowest) at 37ºC in a 5% CO2 
humidified atmosphere. According to previous dose dependent studies, 3×106 HEL cells 
were preincubated for 30 minutes with 1 μM ruxolitinib (Cayman chemical company, Ann 
Arbor, USA) (Heine et al. 2013) or 50 μM 1,2,3,4,5,6-hexabromocyclohexane 
(hexabromocyclohexane, Sigma-Aldrich, Darmstadt, Germany) (Sandberg et al. 2005), and 
treated 1 hour with IL-6 (20 ng/ml) (Niemand et al. 2003). Ruxolitinib and 
hexabromocyclohexane were first dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich), 
but for the applicable final concentration they were dissolved in phosphate-buffered saline 
(PBS). Parallel with JAK1/2 inhibitors, equal amounts of DMSO were added as a control. 
For cell cycle analyses, HEL cells were transferred in 2 ml of RPMI-1640 medium 
(Biowest) in 6-well plates. Seeded HEL cells (starting with 2×106 cells) were incubated 16 
hours with IL-6 (20 ng/ml), with or without 30 minutes preincubation by ruxolitinib (1 μM - 
used concentration match to serum level reached in treated MPN patients (Heine et al. 
2013)) or hexabromocyclohexane (10 and 50 μM). The viable cell counts were performed 
with the use of a trypan blue exclusion technique (Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA).
2.2 Circulating granulocytes of MPN patients
Peripheral blood was obtained from 5 healthy controls and 29 patients diagnosed with MPN 
according to the World Health Organization (WHO) classification. All of the donors signed 
the consent form approved by a local ethical committee in accordance with the Declaration 
of Helsinki. The samples were collected in disodium EDTA and granulocytes were separated 
using a lymphocyte separation medium (LSM, Capricorn Scientific GmbH, Ebsdorfergrund, 
Germany) and lysing solution (0.15 M NH4Cl, 0.1 mM Na2EDTA, 12 mM NaHCO3). 
Besides inverted microscopy (OLYMPUSE PROVIS AX70, Tokyo, Japan), the purity of 
isolated granulocytes was analyzed (CELLQuest software version 3.0) by flow cytometry 
(FACSCalibur, BD Biosciences, San Jose, CA, USA) and proved to be 97% ± 1% CD15 
positive (CD15 Monoclonal Antibody, PerCP-eFluor 710, eBioscience™, San Diego, CA, 
USA). The granulocytes were washed once in PBS and resuspended in RPMI-1640. In order 
to investigate the signaling pathways linked to JAK2, granulocytes were preincubated for 30 
minutes with 1μM ruxolitinib or 50μM hexabromocyclohexane and, subsequently, treated 1 
hour with IL-6 (20 ng/ml). For cell cycle analyses, granulocytes (starting with 2×106 cells) 
were incubated 16 hours with IL-6 (20 ng/ml), with or without 30 minutes preincubation by 
ruxolitinib (1 μM) or hexabromocyclohexane (10 and 50 μM). 10 μM and 50 μM of 
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hexabromocyclohexane similarly (not significantly different) induced the examined 
signaling pathways and cell cycle in healthy granulocytes (except ERK1/2, p<0.01) and 
K562 cells, but because 50 μM hexabromocyclohexane kept tendency for more prominent 
activation we used it in further experiments with IL-6. The viable cell counts were 
performed with the use of a trypan blue exclusion technique (Gibco, Thermo Fisher 
Scientific).
2.3 DNA Sequencing
Genomic DNA was extracted from granulocytes of MPN by the proteinase K and phenol-
chloroform technique. Single nucleotide mutation JAK2V617F was characterized by DNA 
sequencing after PCR amplification performed with wild-type JAK2-specific forward primer 
5′-TGGCAGAGAGAATTTTCTGAACT-3′ and reverse primer 5′-
TTCATTGCTTTCCTTTTTCACA-3′. PCR amplified samples were analyzed by 
sequencing in an automated ABI PRISM 3130 Genetic Analyzer (Applied Biosystems Inc, 
Foster City, CA) with AB DNA Sequencing Analysis Software (v 5.2) by the Big Dye 
Terminator v3.1 Ready Reaction Cycle Sequencing Kit.
2.4 Immunoblotting
Cells were resuspended in RIPA lysis buffer (50 mM Tris-HCl pH 7.6, 150 mM sodium 
chloride, 1% Triton x-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 2 mM 
EDTA and 50 mM sodium fluoride). A protease inhibitor cocktail (Pierce, Thermo Fisher 
Scientific, Waltham, MA, USA) and sodium orthovanadate (Sigma-Aldrich) were added to 
the lysis buffer just prior to use. For Western blotting, equal amounts of protein were run on 
polyacrylamide gels and transferred to polyvinylidene difluoride membrane. Membranes 
were probed for primary antibodies directed against β-actin (Abcam, Cambridge, UK, ab 
1:500), phospho-STAT3/STAT3 (Abcam, cat.no. ab30647/ab137803, 1:500/1:1000), 
phospho-AKT/AKT (Abcam, cat.no. ab192623/ab179463, 1:1000) and phospho-
extracellular signal–regulated kinases 1/2 (ERK1/2, T202/Y204) / ERK1/2 (Cell Signaling 
Technology Inc., Beverly, USA, cat.no. #9101/9102, 1:1000). Peroxidase-conjugated goat 
anti-rabbit (Santa Cruz Biotechnologies, Dallas, USA, cat.no. sc-2054, 1:6000) and goat 
anti-mouse immunoglobulin (Thermo Scientific, Waltham, USA, cat.no. 31430, 1: 5000) 
were used as secondary antibodies. Hyperfilm was developed to visualize the secondary 
antibody by the enhanced chemiluminescence reagent system (GE Healthcare, Amersham, 
UK) according to the manufacturer’s instructions. The phospho-STAT3, phospho-AKT and 
phospho-ERK1/2 levels were estimated by densitometric scanning of the blots using the 
Image Master Total Lab (GE Healthcare, Little Chalfont, UK) software tool and normalized 
to the total STAT3, AKT, and ERK1/2 protein levels, respectively.
2.5 Cell cycle analysis
Following the designated treatments, cell suspensions (1×106/0.4 ml PBS containing 2% 
FBS) were fixed by the drop wise addition of ice-cold 96% ethanol (−20ºC), and then left on 
ice for at least 30 min. After centrifugation at 1000 rpm/5 min, supernatant was carefully 
aspirated and cell pellet resuspended. Afterwards, the single-cell suspensions were incubated 
in a water bath, with 0.5 ml of RNAase solution (1 mg/ml, RNAase A, Thermo Scientific), 
for 20 min at 37ºC, and then with 0.5 ml of propidium iodide (40 μg/ml in PBS w/o FCS, 
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Sigma-Aldrich), for 10 min at room temperature in the dark. The cellular DNA content was 
measured using a CyFlow cytometer (FACSCalibur, BD Biosciences). Usually 3×104 cells 
per sample were analyzed using BDCellQuest Pro software.
2.6 Microarray analysis
For the assessment of mRNA expression levels in CD34+ cells, isolated from peripheral 
blood, we used biological replicates of: 9 healthy donors, 9 PV, 10 ET, and 4 PMF patients 
(Čokić et al. 2015). The human oligo probe set used was the Operon Human Genome Array-
Ready Oligo Set Version 4.0 (Eurofins MWG Operon, Huntsville, AL, USA) and the RNA 
samples were processed and analyzed as reported before using total human universal RNA 
(HuURNA, BD Biosciences, Palo Alto, CA) as a reference in the competitive hybridizations 
(Čokić et al. 2015). The microarray data obtained are available at the Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo; accession no. GSE55976).
2.7 Statistical analysis
The one way ANOVA and Dunnett’s posttest were applied using the Prism 4 software tool 
(GraphPad Software Inc., San Diego, CA, USA). The results are expressed as the mean ± 
SEM, and p-values < 0.05 are considered to be significant.
3. Results
3.1 JAK-STAT signaling interaction with MAPK and PI3K-AKT pathways in circulatory 
CD34+ cells of MPN
We already determined increased levels of CD34+ cells and pro-inflammatory cytokine IL-6 
in the peripheral blood of MPN (Čokić et al. 2015). Using microarray analyses we observed 
the gene expression profile related to PI3K-AKT (Table 1) and MAPK (Table 2) pathways in 
the circulatory CD34+ cells of MPN origin according to the JAK-STAT constitutive 
activation. Their connection and interference with IL-6 and JAK-STAT pathway is presented 
in Figure 1. The stimulation of MAPK pathway was supported by PRKCB and RAP1B that 
stimulated RAF1 expression inhibited by PI3K-AKT pathway (Table 2). Proliferation related 
RAP1A, MAP2K1 and FOS gene expression were increased predominantly in PV and 
JAK2V617F positive ET (Table 2, Fig. 1). As an inhibitor of the PI3K-AKT pathway, PTEN 
gene expression was significantly increased in a JAK2V617F homozygous form of PV 
(Table 1). Linked and increased CDKN1B and CCND3 gene expression, related to cell cycle 
progression, has been observed in MPN (Table 1, Fig. 1). Besides reduced CREB3L4 gene 
expression, linked and significantly downregulated MCL1 gene expression has been detected 
in ET, as an apoptosis inducing factor (Table 1, Fig. 1). We observed the gene expression 
levels linked to PI3K-AKT and MAPK pathways in granulocytes of MPN, but did not find 
the statistical significance (not shown). Here, we revealed the broad activation of the gene 
expression levels related to MAPK pathway in CD34+ cells of MPN. In accordance to the 
low level of CD34+ cells in peripheral blood, we shifted the subsequent protein analyses to 
granulocytes as the JAK2V617F positive or negative myeloid cells.
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3.2 Proinflammatory cytokine IL-6 induction of proliferation related signaling pathways in 
MPN granulocytes
Inflammation biomarkers, such as leukocytes (range 5.2–16.1 × 109/l), thrombocytes (321–
1059 × 109/l), fibrinogen (2.22–5.03 g/l), and erythrocyte sedimentation rate (2–38 mm/h), 
generally demonstrated a tendency toward elevation in MPN (Table 3). Compared to PV, we 
observed reduced levels of erythrocyte and hemoglobin in ET and PMF, where JAK2V617F 
negative PMF demonstrated significantly reduced levels of erythrocyte and hemoglobin 
(Table 3). A marker for the cellular immune system activation, the β2 microglobulin was 
increased in PV and JAK2V617F positive PMF (Table 3). We revealed a continuous IL-6 
activation of STAT3 and AKT signaling up to 1 hour in granulocytes of PV and PMF, while 
dropped below baseline in ET (Fig. 2A, B). IL-6 activation of ERK1/2 signaling was 
constantly increased in PV and PMF and achieved a plateau after 15 minutes, while the 
ERK1/2 phosphorylation was transiently increased in ET (Fig. 2C). To examine the 
JAK2V617F mutation dependence, we compared ET and PMF with or without the mutation 
at different time points during treatment. The JAK2V617F presence significantly (p<0.001) 
and steadily increased activation of JAK2-STAT3 pathway in granulocytes of ET during 1 
hour of incubation, but not consistent in PMF (Fig. 2D). The JAK2V617F mutation 
transiently upregulated the activation of AKT signaling, peaking at 30 minutes, in the 
granulocytes of ET and PMF (p<0.001, Fig. 2E). The activation of ERK1/2 pathway was 
also augmented by JAK2V617F in PMF, but transiently in ET with the highest difference 
after 30 minutes (p<0.001, Fig. 2F). ERK1/2 phosphorylation was in negative correlation 
with the leukocyte number in PV (r=−0.917, p=0.083). In contrast, AKT phosphorylation 
was in positive correlation with the leukocyte number (r=0.865, p=0.026) and fibrinogen 
levels (r=0.887, p=0.018) in PMF. We presented the increased level of inflammation 
biomarkers and time dependent activation of JAK-STAT3, AKT, and ERK1/2 pathways by 
proinflammatory IL-6, affected by JAK2V617F mutation status in MPN.
3.3 JAK1/2 mediated regulation of JAK2-STAT3 signaling pathway by IL-6 in MPN 
granulocytes
JAK1/2 inhibitor ruxolitinib and specific JAK2 inhibitor hexabromocyclohexane prevented 
IL-6 activation of JAK2-STAT3 pathway in the granulocytes of PV, after 1 hour of 
incubation (p<0.001, Fig. 3A). Contrary, IL-6 inhibited STAT3 activation in ET granulocytes 
regardless the JAK2V617F mutation status (Fig. 3B, C). The JAK1/2 and JAK2 inhibitors 
blocked the IL-6 reduction of JAK2-STAT3 signaling in JAK2V617F positive granulocytes 
of ET, while the absence of the mutation enhanced inhibition of JAK2-STAT3 signaling 
(1.75 fold by ruxolitinib, Fig. 3C). The used concentration of ruxolitinib did not prevent the 
constitutive STAT3 phosphorylation in the granulocytes of JAK2V617 positive ET, while 
ruxolitinib and hexabromocyclohexane reduced the phosphorylation of STAT3 in JAK2V617 
negative ET (Fig. 3B, C). IL-6 activation of JAK-STAT3 pathway (1.6 fold) was supported 
by hexabromocyclohexane in JAK2V617F mutated PMF granulocytes (Fig. 3D). 
Furthermore, JAK1/2 and JAK2 inhibitors failed to block the constitutive activation of JAK-
STAT3 signaling in PMF (Fig. 3D, E). IL-6 activated JAK2-STAT3 signaling in PV and 
PMF, but the activation only demonstrated JAK1/2 dependence in PV.
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3.4 JAK1/2 mediated regulation of AKT signaling pathway by IL-6 in MPN granulocytes
Both JAK1/2 and JAK2 inhibitors blocked the IL-6 activation of AKT signaling (1.4 fold) in 
JAK2V617F-positive HEL cells (Fig. 4A). IL-6 enhanced phosphorylation of AKT pathway 
was prevented only by specific JAK2 inhibitor hexabromocyclohexane in PV granulocytes 
(Fig. 4B). IL-6 reduced AKT phosphorylation in ET was reversed and stimulated by JAK1/2 
and JAK2 inhibitors (up to 1.7 fold) in JAK2V617F mutated ET granulocytes (Fig. 4C, D). 
Hexabromocyclohexane and ruxolitinib also reduced AKT phosphorylation in JAK2V617F 
negative ET (Fig. 4D). IL-6 activation of AKT signaling (1.4 fold) was blocked by both 
JAK1/2 and JAK2 inhibitors in PMF (Fig. 4E, F). IL-6 failed to induce AKT signaling in 
granulocytes of healthy controls and K562 cells, while ruxolitinib (1.4 fold) activated in 
K562 cells and hexabromocyclohexane (1.3 fold) in granulocytes (not shown). IL-6 
activation of AKT signaling is JAK1/2 dependent in HEL cells and granulocytes of PV and 
PMF.
3.5 JAK1/2 mediated regulation of MAPK signaling pathway by IL-6 in MPN granulocytes
IL-6 enhanced phosphorylation of ERK1/2 pathway in granulocytes of healthy subjects only 
in co-treatment with hexabromocyclohexane (p<0.001, 1.44 fold, Fig. 5A). IL-6 enhanced 
phosphorylation of the ERK1/2 pathway, in PV granulocytes, was not affected by JAK1/2 
and JAK2 inhibitors (Fig. 5B). IL-6 activated ERK1/2 signaling only in JAK2V617 negative 
ET (Fig. 5C, D). Moreover, ruxolitinib largely stimulated ERK1/2 signaling in ET (up to 6.5 
fold) regardless the JAK2V617F presence, compared to modest hexabromocyclohexane 
increase (Fig. 5C, D). IL-6 activation of ERK1/2 signaling was enhanced by non-specific 
JAK1/2 inhibitor ruxolitinib (up to 1.6 fold), reduced by specific JAK2 inhibitor 
hexabromocyclohexane (up to 1.7 fold), and not affected by JAK2V617F mutation status in 
PMF granulocytes (Fig. 5E, F). Individually, IL-6 (1.46 fold) and hexabromocyclohexane 
(1.7 fold) activated ERK1/2 signaling in K562 cells (not shown), but not in granulocytes of 
healthy controls (Fig. 5A). Moreover, hexabromocyclohexane supported IL-6 activation of 
ERK1/2 signaling in K562 cells (1.6 fold, not shown). Ruxolitinib activated largely ERK1/2 
signaling in the granulocytes of ET and PMF patients.
3.6 JAK1/2 mediated regulation of cell cycle induced by IL-6
To study the JAK2-STAT3 mediated IL-6 induction of myeloproliferation, we demonstrated 
that IL-6 with or without JAK1/2 inhibitors double increased apoptosis and 1.5 fold reduced 
granulocyte frequency of G0/G1 phase in K562 cells (Fig. 6A). Ruxolitinib reversed IL-6 
reduction of HEL cells quantity (as a cell proliferation model) in G2M phase of cell cycle 
after 16 hours of incubation (p<0.05, Fig. 6B). S phase was not significantly changed by 
IL-6 and JAK1/2 inhibitors in granulocytes of healthy donors (Fig. 6C). Regarding the S and 
G2/M phases, the highest quantity of positive granulocytes was observed for PV (Fig. 6D). 
The thrombocyte quantity was in positive correlation with the PV granulocytes arrested in S 
phase of cell cycle (r=0.997, p=0.003). The highest number of granulocytes in G0/G1 phase 
was observed in ET (Fig. 6E), especially JAK2V617F negative ET (not shown). The G0G1 
portion of granulocytes was significantly reduced in PMF by IL-6 regardless JAK1/2 
inhibition (p<0.01, Fig. 6F). In addition, IL-6 largely increased the percentage of ET- (2.2 
fold, p<0.001) and PMF- (2.8 fold, p<0.001) derived granulocytes in S phase of cell cycle 
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that was completely abolished by JAK1/2 and JAK2 inhibitors (Fig. 6E, F). Regarding cell 
survival, both ruxolitinib and hexabromocyclohexane with IL-6 increased apoptosis of PMF 
granulocytes (up to 1.6 fold, p<0.05, Fig. 6F). JAK1/2 and JAK2 inhibitors reduced 
apoptosis in JAK2V617F positive, but increased in JAK2V617F negative granulocytes of 
PMF patients (p<0.01, not shown). IL-6 stimulation of DNA replication is JAK1/2 mediated 
in granulocytes of MPN.
4. Discussion
JAK2-STAT3 signaling activated the PI3K/AKT and MAPK pathways (Araki 2016). As 
major regulators of cell survival and proliferation, the MAPK and PI3K-AKT pathways 
were activated during oncogenesis due to their cross-activation and pathway convergence 
that can facilitate the acquisition of resistance to therapeutics targeting only one pathway 
(Mendoza 2011). IL-6 stimulated MAPK, PI3K-AKT and via IL-6 receptor STAT3 
phosphorylation, while the last one was not prevented by MAPK and PI3K signaling 
inhibition (Hideshima et al. 2001; Fahmi et al. 2013). IL-6 induced MAPK phosphorylation 
was partially blocked by PI3K signaling inhibition, while PI3K-AKT phosphorylation was 
not prevented by MAPK signaling inhibition (Hideshima et al. 2001). We observed that IL-6 
increased phosphorylation of ERK1/2 signaling was prevented by specific JAK2 inhibition 
in PMF granulocytes. However, only non-specific JAK1/2 inhibition largely stimulated 
ERK1/2 signaling in granulocytes of ET and PMF patients.
A difference in the molecular mechanism of inhibition between the JAK1/2 inhibitor 
ruxolitinib and the specific JAK2 inhibitor hexabromocyclohexane can explain this paradox. 
Hexabromocyclohexane reduced JAK2 tyrosine kinase autophosphorylation by inhibiting 
ligand dependent activation, while ruxolitinib acted as an ATP-competitive inhibitor of 
JAK1/2 kinase activation of downstream pathways (Sandberg et al. 2005; Quintás-Cardama 
et al. 2010) The persistence of JAK2 inhibition was associated with the reversible activation 
of JAK–STAT signaling and heterodimerization between the activated JAK2 and JAK1 or 
TYK2, consistent with the activation of JAK2 in trans by other JAK kinases in MPN 
(Koppikar et al. 2012). Furthermore, JAK1/2 inhibition can potentiate the TYK2-dependant 
activation of ERK1/2, while the specific inhibition of JAK2 may destabilize a complex with 
IL-6 receptor diminishing ERK1/2 activation.
PI3K inhibition blocked IL-6-induced G1/S phase transition and G1 growth arrest 
(Hideshima et al. 2001). IL-6 induction of G1-arrested cells was sufficient to induce S phase 
entry and prevent apoptosis (Côté et al. 2005). IL-6 increased percentage of cells in S phase 
through the activation of JAK2-STAT3 and ERK1/2 pathways (Suh et al. 2008). Activated 
STAT3 increased proliferation and tumor-promoting inflammation, while also inhibited 
apoptosis (Klein et al. 2014; Yu et al. 2009). In contrast, the parallel inhibition of IL-6/
STAT3 and ERK1/2 pathways led to strong induction of apoptosis (Chatterjee et al. 2004). 
We also demonstrated that pro-inflammatory IL-6 generally increased percentage of MPN 
granulocytes in S phase, through JAK1/2 control, promoting cell proliferation.
In vitro proliferation of erythroid cells from JAK2V617F-positive MPN patients was 
synergistically regulated by STAT, PI3K/AKT and MAPK pathways, while PI3K inhibition 
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blocked MAPK activation (Wolf et al. 2013). An increased phosphorylation of STAT3 in the 
JAK2V617F positive MPN patients, with no positive correlation with JAK2V617F allele 
burden has been reported (Risum et al. 2011). Moreover, the efficacy of ruxolitinib was 
irrelevant to the JAK2V617F mutation status in patients with PMF (Chen et al. 2016). In 
addition, an increased phosphorylation of STAT3 was not affected by JAK2V617F mutation 
status in the bone marrow of PV and ET (Teofili et al. 2007). The deletion of Stat3 slightly 
reduced the erythrocytes and hematocrit parameters, increased platelets and neutrophils, and 
markedly reduced the survival of Jak2V617F knock-in mice (Yan et al. 2015; Grisouard et 
al. 2015). According to the presented results, an overview of the JAK1/2 mediated IL-6 
induction of the proliferation related pathways is shown in Table 4. Furthermore, it has been 
reported that ruxolitinib reduced constitutive STAT3 phosphorylation with a modest effect 
on AKT signaling in the JAK2V617F mutated HEL cell line (Quintás-Cardama et al. 2010). 
Another study showed that the PI3K/AKT pathway is involved in a malignant 
transformation by JAK2V617F mutation (Kamishimoto et al. 2011). We demonstrated that 
IL-6 inhibition of AKT signaling is overturned by both JAK2 and JAK1/2 inhibitors in the 
JAK2V617F positive ET granulocytes. Contrarily, IL-6 activation of AKT signaling is 
prevented by JAK2 and JAK1/2 inhibition in PMF, regardless of the JAK2V617F status.
The PI3K/AKT/mTOR inhibition induced a cell-cycle growth arrest and apoptosis of the 
primary CD34+ MPN cells, synergistically supported by JAK2 inhibition, while sparing the 
normal CD34+ cells (Fiskus et al. 2013). Moreover, PI3K/mTOR inhibitor in combination 
with the JAK1/2 inhibitor ruxolitinib prolonged survival and improved clinical parameters in 
conditional Jak2V617F knock-in mice (Bartalucci et al. 2013). In a Phase I/II trial with 
mTOR inhibitor everolimus, 60% of PMF patients showed improvement in constitutional 
symptoms and a decrease in spleen enlargement although to a lesser extent than JAK 
inhibitors, with no changes in mutant allele burden and cytokine profile (Guglielmelli et al. 
2011). Therefore, the PI3K/AKT/mTOR signaling pathway is an auxiliary structure for the 
regulation of proliferation in MPN.
5. Conclusions
IL-6 induced DNA replication in granulocytes, thus preventing apoptosis via the JAK1/2 
stimulation in MPN. IL-6 stimulated JAK2-STAT3 and AKT signaling in PV and PMF, but 
reduced in ET. JAK1/2 inhibition largely stimulated MAPK signaling in ET and PMF, 
regardless JAK2V617F mutation. The treatment that integrates the inhibition of JAK2-
STAT3 and MAPK pathways may be crucial to overcome the cross-activation responsible for 
limitations in the current targeted therapy of MPN.
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JAK-STAT signaling stimulation of MAPK and PI3K/AKT pathways in CD34+ cells of 
MPN origin (correspond to Tables 1 and 2). (+p) phosphorylation, (-p) dephosphorylation; 
→ stimulation, ┴ inhibition; white boxes represent down-regulated genes, gray boxes 
mixed gene expression, black boxes up-regulated genes vs. controls, while white boxes with 
an intermittent edge represent sporadically expressed genes in MPN vs. control.
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Activation of proliferation related signaling pathways by IL-6 in MPN granulocytes. Time 
scale of IL-6 (20 ng/ml) activation of (A) JAK/STAT3; (B) AKT and (C) ERK1/2 signaling 
in granulocytes of polycythemia vera (PV, n = 6), essential thrombocythemia (ET, n = 8) and 
primary myelofibrosis (PMF, n = 8). *p < 0.05, **p < 0.01, ***p < 0.001 vs. non-treated 
cells (0). IL-6 activation of (D) JAK/STAT3; (E) AKT and (F) ERK1/2 signaling in ET and 
PMF according to JAK2V617F presence during 1 hour of incubation. (n = 4) Values are 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. non-mutated cells.
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IL-6 activation of STAT signaling in PV and PMF as well as inhibition in ET granulocytes. 
IL-6 (20 ng/ml) activation of JAK/STAT3 signaling in (A) polycythemia vera (PV), (B) 
essential thrombocythemia (ET) with JAK2V617F (JAK2+), (C) ET without JAK2V617F 
(JAK2-), (D) primary myelofibrosis (PMF) JAK2+, (E) PMF JAK2-, in the presence of 
ruxolitinib (Ruxo) and hexabromocyclohexane (Hexa) after 1 hour of incubation. Values are 
mean ± SEM (n=4). *p < 0.05, **p < 0.01, ***p < 0.001 vs. non-treated cells/Control; #the 
same vs. IL-6 treated cells.
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JAK1/2 dependent activation of AKT pathway by IL-6 in PV and PMF besides inhibition in 
ET granulocytes. IL-6 (20 ng/ml) activation of AKT signaling in (A) HEL cells, (B) 
polycythemia vera (PV), (C) essential thrombocythemia (ET) with JAK2V617F (JAK2+), 
(D) ET without JAK2V617F (JAK2-), (E) primary myelofibrosis (PMF) JAK2+, (F) PMF 
JAK2-, in the presence of ruxolitinib (Ruxo) and hexabromocyclohexane (Hexa) after 1 hour 
of incubation. Values are mean ± SEM (n=4). *p < 0.05, **p < 0.01, ***p < 0.001 vs. non-
treated cells/Control; #the same vs. IL-6 treated cells.
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IL-6 activation of MAPK pathway in PV and PMF then inhibition in JAK2+ ET 
granulocytes. IL-6 (20 ng/ml) activation of ERK1/2 signaling in (A) healthy controls, (B) 
polycythemia vera (PV), (C) essential thrombocythemia (ET) with JAK2V617F (JAK2+), 
(D) ET without JAK2V617F (JAK2-), (E) primary myelofibrosis (PMF) JAK2+, (F) PMF 
JAK2-, in the presence of ruxolitinib (Ruxo) and hexabromocyclohexane (Hexa) after 1 hour 
of incubation. Values are mean ± SEM (n=4). *p < 0.05, **p < 0.01, ***p < 0.001 vs. non-
treated cells/Control; ###p < 0.001 vs. IL-6 treated cells.
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IL-6 increased the percentage of MPN granulocytes in S phase of cell cycle mediated by 
JAK1/2. IL-6 (20 ng/ml) induction of cell cycle in (A) K562 cells (n=3), (B) JAK2V617F 
mutated HEL cells (n=3), (C) healthy donors (n=3), (D) polycythemia vera (PV, n=4), (E) 
essential thrombocythemia (ET, n=8) and (F) primary myelofibrosis (PMF, n=8) treated with 
Ruxolitinib (R) or Hexabromocyclohexane (H) after 16 hours of incubation (gray box). 
Values are mean±SEM.
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Table 1:
PI3K/AKT pathway related gene expression in circulatory CD34+ cells of MPN origin.









CDK4 cyclin-dependent kinase 4 −0.9±0.3 −1.8±0.3 −1.5±0.7
−1.8± 0.3
** −1.7±0.2





PPP2R5C protein phosphatase 2, 





MCL1 myeloid cell leukemia 
sequence 1
3±0.6 1.7±1 3.2±0.3 1.9±0.6
2.6±0.2
* 2±0.8











** 2.4±0.8 2.6±0.1 2.5±0.7
JAK1 Janus kinase 1 0.9±0.2 1.4±0.03
1.7±0.1
























* −0.1±0.2 −1.6±0.4 −1.3±0.2 −0.3±0.5




* 2.9±0.6 3.1 2.6±0.7





FN1 fibronectin 1 −3.2±0.4
−4.2±0.1
* −4.1 −4±0.7 −3
−3.8±0.3
**
STK11 serine/threonine kinase 11 1.8±0.4
2.5±0.4
* 2.1±0.3 2.5±1 1.4±0.7 1.7±0.8
NFKB1 nuclear factor of kappa 
light polypeptide gene 




PGF placental growth factor −2.5±0.9 −3.1±0.3 −3.8±0.4 −2.6±0.6 −2.9±0.9 −3.4±0.7
ITGB7 integrin, beta 7 −1.5±0.6 −1.7±0.5 −2±0.6 −2±0.5 −2.1±0.2
−2.3±0.3
*




* −0.4±0.4 −0.2 −0.1±0.3 −0.1±0.2




* −0.1±0.4 0.3±0.2 −0.1±0.2













Subotički et al. Page 20









CDC37 cell division cycle 37 
homolog






AKT2 v-akt murine thymoma 
viral oncogene homolog 2
0.9±0.2 0.7±0.4 1.3±0.1 0.8±0.4 1.1±0.6 0.9±0.3
GSK3B glycogen synthase kinase 
3β
1.5±0.6 1.7 0.9±0.3 0.8±0.7 1.3 0.9±0.2
CDKN1A cyclin dependent kinase 
inhibitor 1A
2.4±0.6 2.5±0.9 1.8±0.6 2.7±1.5 2.1 2.2±0.3
CDKN1B cyclin-dependent kinase 
inhibitor 1B
1.1±0.9 1.8±0.4 2±0.6 1.4±0.6 1.1±0.7 1.5±0.8
CDK2 cyclin-dependent kinase 2 −0.8±0.2 0.6
RBL2 retinoblastoma-like 2 2.4±0.5 2.4±0.2 2.2±0.3 2.7±0.6 2.3±0.1 1.9±0.6
CREB3L4 cAMP responsive element 
binding protein 3-like 4
2.6±0.7 2.1±0.2 1.9±0.5 1.6±0.5 1.5±0.2 1.3
BCL2L11 BCL2-like 11 (apoptosis 
facilitator)
1.4±0.03 1.2
BCL2 B-cell CLL/lymphoma 2 0.7 1.1 1.3
MCL1 myeloid cell leukemia 
sequence 1 (BCL2-related)
3±0.6 1.7±1 3.2±0.3 1.9±0.6
2.6±0.2
* 2±0.8





htz-heterozygosity, hom – homozygosity, no mut – no mutation
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Table 2:
MAPK signaling pathway related gene expression in circulatory CD34+ cells of MPN origin.














DUSP3 dual specificity 
phosphatase 3
−0.5±0.1 −0.4±0.3 −0.4±0.2 −0.2±0.1 −0.5±0.1 −0.3±0.1























** −0.6±0.5 −0.8±0.2 −0.3±0.6




** 2.4±0.8 2.6±0.1 2.5±0.7
MAP3K4 Mitogen-activated protein 
kinase kinase kinase 4
−2.3±0.2 −3.3±0.3
−4.1±0.04
** −3.8 −3.3± 0.4
MAPK8IP2 mitogen-activated protein 







ELK4 ELK4, ETS-domain 




* 1.9±0.6 1.9±0.4 1.4±0.3
CACNA1S calcium channel, voltage-




* −2.5± 0.2 −2.2± 0.8 −2.1±1.3 −2.3±0.8
NFKB1 nuclear factor of kappa 
light polypeptide gene 








* 0.9±1.2 0.3±0.6 −0.3±0.6 0.2±0.4




* 3.3±0.2 3.2±0.5 3.2±0.5 3.2±0.3
RAP1A RAP1A, member of RAS 
oncogene family
0.9±0.4 1.3±0.5 1.5±0.4 1.3±0.2 0.7±0.4 0.8±0.5











* 3.4±1.1 3.6±0.8 2.3±0.8 2.4±1
MAP3K7 mitogen-activated protein 
kinase kinase kinase 7
0.6±0.2
1.6±0.4
* 0.7±0.2 0.8±0.5 0.2 0.3




* −0.4± 0.4 −0.2 −0.1±0.3 −0.1±0.2
GNG12 guanine nucleotide 
binding protein, gamma 12
0.3±0.6 0.3±0.4
−0.5± 0.3
* −0.1±0.4 0.3±0.2 −0.1±0.2
PRKCB protein kinase C, beta 1.8 2.6±0.03 2.3±0.4 2.3±0.4 2.3±0.4 1.4±0.9
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KRAS v-Ki-ras2 Kirsten rat 
sarcoma viral oncogene 
homolog
1.2±0.6 0.9±0.3 0.6±0.1 0.8±0.3 0.5±0.2 0.6±0.5
GRB2 growth factor receptor-
bound protein 2
1.7 1.9±0.1 2.1 1.5
RAF1 v-raf-1 murine leukemia 
viral oncogene homolog 1
1.7±0.3 1.9±0.3 2.2±0.4 2±0.3 2±0.1 1.9±0.4
MAP2K1 mitogen-activated protein 
kinase kinase 1
0.5±0.3 1.1±0.3 1±0.2 0.7±0.2 0.6 0.2±0.5
MAPK1 mitogen-activated protein 
kinase 1
1.5±0.3 1.2±0.1 1.7 −1.9 0.8
MKNK2 MAP kinase interacting 
serine/threonine kinase 2
1.4±0.7 1.7±0.2 1.6±0.4 1.7±0.8 1.7±1.03 1.6±0.9
MYC v-myc myelocytomatosis 
viral oncogene homolog
−1.9±0.3 −1.3±0.7 −1.6±0.5 −1.7±0.3 −2.3±0.2 −1.4±1.02




p<0.05 MPN vs. Control
htz-heterozygosity, hom – homozygosity, no mut – no mutation
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Table 4:
Overview of IL-6 induction of proliferation related signaling pathways in MPN granulocytes.
IL-6 PV ET PMF
Inhibitors JAK2+ JAK2− JAK2+ JAK2− JAK2+
STAT3
JAK1/2 ↓ ↓ ↑
JAK2 ↓ ↓ ↑ ↑
AKT
JAK1/2 ↑ ↑ ↓ ↓
JAK2 ↓ ↑ ↓ ↓
MAPK
JAK1/2 ↑ ↑↑ ↑ ↑
JAK2 ↑ ↓ ↓
Solid cells: IL-6 stimulation, empty cells: IL-6 inhibition of signaling pathways, Inhibitors ↑-increase or ↓-decrease IL-6 effect, JAK2+: 
JAK2V617F positive and JAK2-: JAK2V617F negative MPN
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